Time to End the Use of Genetic Test Results in Life Insurance Underwriting.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Factors influencing Patient Preferences for BRCA Testing and Adjuvant Therapy in HER2-Negative Early Breast Cancer in the United States: Best-Worst Scaling and Discrete Choice Experiment.The patient · 2026
   Article
2. How to implement a radiologist led whole-body MRI screening program.Radiology advances · 2026
   Review
3. Cardiovascular genetic counselor decision making about discussing life insurance with patients.Journal of genetic counseling · 2025
   Article
4. The silent spread: exploring diverse metastatic pathways in high-grade serous ovarian cancer.Frontiers in medicine · 2025
   Review
5. Principles and Policy Recommendations for Comprehensive Genetic Data Governance.Proceedings of the AAAI/ACM Conference on AI, Ethics, and Society · 2025
   Article
6. Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges.Health economics, policy, and law · 2024
   Article
7. Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs.Familial cancer · 2024
   Review
8. Community concerns about genetic discrimination in life insurance persist in Australia: A survey of consumers offered genetic testing.European journal of human genetics : EJHG · 2024
   Article
9. The Legal Uncertainties of Sociogenomic Polygenic Scores.Harvard journal of law & technology · 2024
   Article
10. Attitudes of Australian dermatologists on the use of genetic testing: A cross-sectional survey with a focus on melanoma.Frontiers in genetics · 2022
    Article
11. Genetic information, insurance and a pluralistic approach to justice.Journal of medical ethics · 2021
    Article
12. Long-awaited progress in addressing genetic discrimination in the United States.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
13. Genetic testing and insurance implications: Surveying the US general population about discrimination concerns and knowledge of the Genetic Information Nondiscrimination Act (GINA).Risk management and insurance review · 2021
    Article
14. A survey of U. S. state insurance commissioners concerning genetic testing and life insurance: Redux at 27.Journal of genetic counseling · 2020
    Article
15. Establishing the International Genetic Discrimination Observatory.Nature genetics · 2020
    Article
16. Genetic discrimination by Australian insurance companies: a survey of consumer experiences.European journal of human genetics : EJHG · 2020
    Article
17. APOL1 Genetic Testing in Living Kidney Transplant Donors.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Review
18. Prohibiting Genetic Discrimination to Promote Science, Health, and Fairness.American journal of human genetics · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as